Alpine Immune Sciences

175 articles about Alpine Immune Sciences

• Alpine Immune Sciences Announces Poster Presentations at EULAR 2020

  5/29/2020

  Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that the company will present two posters at the EULAR 2020 E-Congress, taking place virtually June 3-6, 2020. Details of the presentations are as follows: Presentation Title : B Cell Modulatory Variant TNF Receptor

• Alpine Immune Sciences to Participate in Fireside Chat at the Jefferies 2020 Virtual Global Healthcare Conference

  5/26/2020

  Alpine Immune Sciences, Inc., a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, announced its participation in an analyst-led fireside chat at the Jefferies Virtual Global Healthcare Conference on Tuesday, June 2, at 10:00 a.m. ET.

• Alpine Immune Sciences Reports First Quarter 2020 Financial Results and Provides Company Update

  5/14/2020

  Alpine Immune Sciences, Inc., a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, provided a corporate update and reported financial results for the first quarter ended March 31, 2020.

• Alpine Immune Sciences Presents Design of the ALPN-202 Phase 1 Study (NEON-1) at AACR Virtual Annual Meeting I

  4/27/2020

  Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today presented the design of NEON-1, the first-in-human study of ALPN-202, a first-in-class, conditional CD28 costimulator and dual checkpoint inhibitor, at the

• Alpine Immune Sciences Announces Poster Presentation at AACR Virtual Annual Meeting I

  4/20/2020

  Alpine Immune Sciences, Inc. announced the company will present a poster at the AACR Virtual Annual Meeting I, taking place April 27-28, 2020.

• Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results

  3/30/2020

  Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2019.

• Alpine Immune Sciences’ ALPN-101 Receives FDA Orphan Drug Designations for the Prevention and Treatment of Acute Graft Versus Host Disease

  3/18/2020

  Company to Hold Conference Call to Discuss Fourth Quarter and Full Year 2019 Results on March 30, 2020

• Alpine Immune Sciences Announces Cancellation of Presentation and Webcast at the Cowen 40th Annual Healthcare Conference

  3/2/2020

  Alpine Immune Sciences Announces Cancellation of Presentation and Webcast at the Cowen 40 th Annual Healthcare Conference

• Alpine Immune Sciences to Present at Two Upcoming Healthcare Investor Conferences on March 2020

  2/25/2020

  Alpine Immune Sciences, Inc., a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, announced the company will present at two upcoming investor healthcare conferences in March.

• Alpine Immune Sciences Presents New Preclinical Data at 2020 Crohn’s & Colitis Congress  ALPN-101 demonstrates efficacy in treatment of chronic inflammatory bowel disease in both in vivo and in vitro models

  1/24/2020

  Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, presented new preclinical data on its lead autoimmune/inflammatory clinical program, ALPN-101, at the 2020 Crohn’s & Colitis Congress in Austin, Texas.

• Alpine Immune Sciences Announces Poster Presentation at 2020 Crohn’s & Colitis Congress

  1/6/2020

  Alpine Immune Sciences Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present a poster at the 2020 Crohn’s & Colitis Congress

• Alpine Immune Sciences Presents ALPN-101 Phase 1 Healthy Volunteer Study Data and Details of Upcoming Phase I/II BALANCE GVHD Study at the 61st American Society of Hematology Annual Meeting

  12/9/2019

  Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, presented Phase 1 data yesterday from the healthy volunteer study of ALPN-101,

• Alpine Immune Sciences to Participate in Fireside Chat at 31st Annual Piper Jaffray Healthcare Conference

  11/26/2019

  Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced participation in an analyst-led fireside chat at the 31st Annual Piper Jaffray Healthcare Conference

• Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2019 Financial Results

  11/13/2019

  Company Advancing ALPN-101 into a Phase 1/2 Acute Graft versus Host Disease Study (BALANCE)

• Alpine Immune Sciences Presents New ALPN-101 Preclinical Data at the 2019 American College of Rheumatology (ACR) Annual Meeting

  11/12/2019

  Preclinical activity suggests unique effectiveness across a range of rheumatic and other inflammatory diseases

• Alpine Immune Sciences Presents New Preclinical Data at The Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting

  11/8/2019

  Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today presented new preclinical data on ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of advanced malignancies, at The Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting

• Alpine Immune Sciences Completes Enrollment of Phase I Study of ALPN-101 and Announces Third Quarter Conference Call

  10/30/2019

  Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced that it has completed enrollment in all planned cohorts of the Phase I study of its lead program, ALPN-101, a first-in-class dual ICOS/CD28 antagonist

• Alpine Immune Sciences Announces Upcoming Scientific Presentations at SITC and ACR/ARHP 2019 Annual Meetings

  10/2/2019

  Alpine Immune Sciences, Inc. announced planned poster presentations at upcoming scientific meetings highlighting new preclinical data on the Company’s lead programs: ALPN-101, a first-in-class dual CD28/ICOS inhibitor for the treatment of autoimmune diseases, and ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancers.

• Alpine Immune Sciences to Present at 2019 Ladenburg Thalmann Healthcare Conference

  9/17/2019

  Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will present at the 2019 Ladenburg Thalmann Healthcare Conference on Tuesday, September 24, 2019 at 3:00 p.m. Eastern Time in New York, NY.

• Alpine Immune Sciences Provides Pipeline Update and Reports Second Quarter 2019 Financial Results

  8/13/2019

  ALPN-101 Progresses to Multiple-Ascending Dose Cohorts of Phase I Study